- Fellowship - University of Michigan Medical Center (2009-2010), Transplant Hepatology
- Fellowship - University of Michigan Medical Center (2006-2009), Gastroenterology
- Residency - University of Washington School of Medicine (2003-2006), Internal Medicine
- Medical School - University of Michigan Medical School (1999-2003)
Amit Singal, M.D.
Medical Director of the Liver Tumor Program and Clinical Chief of Hepatology
- Dedman Family Scholar in Clinical Care
- David Bruton, Jr. Professorship in Clinical Cancer Research
- Internal Medicine - Digestive & Liver Diseases
- Liver Cancer
Amit Singal, M.D., M.S., has had several patients who were cured of liver cancer, but he would like to have many more.
A hepatologist, Dr. Singal treats patients with liver disease and cares for transplant recipients pre- and post-surgery. He is an Associate Professor of Internal Medicine in the Division of Digestive and Liver Diseases at UT Southwestern Medical Center. He is Medical Director of the UT Southwestern Liver Tumor Program and Clinical Chief of Hepatology.
Most of Dr. Singal’s research examines how to diagnose and treat liver cancer before it becomes incurable. Unfortunately, he says, too many patients are diagnosed when their cancer is already in the advanced stages.
“If we diagnose liver cancer at an early stage, we can often cure it,” Dr. Singal says. “Patients can live over five years if we diagnose and treat liver cancer early. However, when it’s found at a late stage, the average survival is typically less than one year.”
Dr. Singal is a native of the Detroit area and completed most of his medical education at the University of Michigan. He earned his medical degree and a Master of Science at the University of Michigan, as well as fellowships in gastroenterology and transplant hepatology. Dr. Singal completed his internal medicine residency at the University of Washington in Seattle.
Dr. Singal began his career at UT Southwestern in 2010. He was drawn to Texas and UT Southwestern because liver cancer is a particular problem in Texas, and he believes UT Southwestern is the best place to help do something about it.
“Texas has the second-highest incidence rate for liver cancer across the country,” Dr. Singal says. “Furthermore, it’s currently the fastest-growing cancer in Texas.”
Dr. Singal is doing everything he can to change that. He is working with primary care physicians and other hepatologists to better understand and follow guidelines for liver cancer screening. People with liver disease, who are at risk for liver cancer, should be screened every six months, but less than 20 percent of patients are currently having this done.
He’s also hopeful about new advances in medicine.
“We’ve made incredible strides in treatments for liver cancer already over the past decade. Over the next decade, we will see even more advances in therapeutic options for this cancer.”
Dr. Singal is board certified in internal medicine, gastroenterology, and transplant hepatology. He is also a member of the American Gastroenterology Association, the American College of Gastroenterology, the American Association for the Study of Liver Diseases, and the International Liver Cancer Association.
Dr. Singal has received numerous grants, including those from the National Institute of Health (NIH), Cancer Prevention Research Institute of Texas (CPRIT), and Department of Defense (DOD). His research has been published in many peer-reviewed publications, such as JAMA, Gastroenterology, Hepatology, Cancer Epidemiology Biomarkers & Prevention, and Clinical Gastroenterology and Hepatology. Dr. Singal also lectures frequently on liver cancer throughout the country.
In 2018, he was named a Super Doctor by Texas Monthly.
During his off time, Dr. Singal likes to travel internationally. And he loves to cheer on his home teams – the Michigan Wolverines, Detroit Lions, and Detroit Red Wings – when they are in Dallas.
Meet Dr. Singal
Amit Singal, M.D., M.S., has declared war on liver cancer, which is the ninth leading cause of cancer-related death in the U.S. and the fastest-growing cancer in Texas.
“I’m going to work as hard as I can to give my patients the care they deserve. Cancer patients want a doctor who cares and will go the extra mile. I’m dedicated to doing that.”
A hepatologist, Dr. Singal treats patients with liver disease and cares for transplant recipients pre- and post-surgery. He is an Associate Professor of Internal Medicine in the Division of Digestive and Liver Diseases at UT Southwestern Medical Center. Additionally, he serves as Medical Director of the UT Southwestern Liver Tumor Program and Clinical Chief of Hepatology.
Dr. Singal came to Texas and UT Southwestern so he could help do something about liver cancer in the Lone Star State. Texas has the second-highest incidence rate of liver cancer in the nation, and he believes that it will only become an increasingly more important problem over the next two decades. Dr. Singal believes UT Southwestern has the cutting-edge therapies and committed doctors who can make a difference in this field.
Most of his research examines how to diagnose and treat liver cancer when curative therapies exist. He believes it is important to work with primary care physicians and other hepatologists to follow published guidelines for liver cancer screening among at-risk patients. People with liver diseases who are at risk for liver cancer should get screened every six months, but less than 20 percent of patients are currently having this done. Dr. Singal is dedicated to improving this care over the next several years.
Dr. Singal also works closely with patients with liver cancer to help them choose the best treatment options, and he is willing to do whatever it takes to get his patients through the process.
- American College of Gastroenterology (2006)
- American Association for the Study of Liver Diseases (2006)
- International Liver Cancer Association (2007)
- Alpha Omega Alpha Medical Honors Society 2002
- Huesby Teaching Award 2006
- Phi Kappa Phi National Honor Society 2008
- AASLD Advanced Transplant Hepatology Fellowship Award 2009
- Dedman Family Scholar in Clinical Care 2010
- Super Doctors Rising Stars 2012
- Lyman Bilhartz Memorial Teaching Award 2012
- International Liver Cancer Association Junior Investigator Award 2013
- Blue Faery Award for Excellence in Liver Cancer Research 2017
- UT Southwestern Internal Medicine Outstanding Research Mentor 2018
Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.
Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA Journal of general internal medicine 2012 Jul 27 7 861-7
Improving Hepatocellular Carcinoma Screening: Applying Lessons From Colorectal Cancer Screening.
Singal AG, Tiro JA, Gupta S Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2012 Nov
Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?
Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM The American journal of gastroenterology 2013 Jan
Improved Post-Transplant Survival in the United States for Patients with Cholangiocarcinoma After 2000.
Salgia RJ, Singal AG, Fu S, Pelletier S, Marrero JA Digestive diseases and sciences 2013 Mar
Failure rates in the hepatocellular carcinoma surveillance process.
Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M, Lee WM, Marrero JA, Tiro JA Cancer prevention research (Philadelphia, Pa.) 2012 Sep 5 9 1124-30
Recent advances in the treatment of hepatocellular carcinoma.
Padhya KT, Marrero JA, Singal AG Current opinion in gastroenterology 2013 Mar
Role of liver transplantation in the treatment of cholangiocarcinoma
Singal, A. Welling, TW. Marrero, JA. Expert Rev Anticancer 2009 9 (4) 491-502
Clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care center
Singal, AG. Rakoski, MO. Salgia, R. Pelletier, S. Welling, TH. Fontana, RJ. Lok, AS. Marrero, JA Alimentary, Pharmacology and Therapeutics 2010 31 (6) 625-633
Chronic disease management for patients with cirrhosis
Volk, ML. Piette, JD. Singal, AG. Gastroenterology 2010 139 (1) 14-16
Patient Involvement in Healthcare is Associated With Higher Rates of Surveillance for Hepatocellular Carcinoma.
Singal AG, Volk ML, Rakoski MO, Fu S, Su GL, McCurdy H, Marrero JA Journal of clinical gastroenterology 2011 May 727-32
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.
Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS, Marrero JA Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012 May 21 5 793-9
Surveillance for Hepatocellular Carcinoma: How Can We Do Better?
Hassett M, Yopp AC, Singal AG The American journal of the medical sciences 2013 Feb
- Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.
- Quality of care in the cirrhotic patient
- Impact of patient and physician knowledge/attitudes on receipt of care
- Effectiveness of surveillance for hepatocellular carcinoma
- Liver Cancer
- Liver Disease
Q&A by Dr. Singal
Dr. Amit Singal on delivering patient care.
Showing 1 locations